Literature DB >> 17441749

Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor.

Vyacheslav M Abramov1, Valentin S Khlebnikov, Anatoly M Vasiliev, Igor V Kosarev, Raisa N Vasilenko, Nataly L Kulikova, Anna V Khodyakova, Valentin I Evstigneev, Vladimir N Uversky, Vladimir L Motin, Georgy B Smirnov, Robert R Brubaker.   

Abstract

The virulence antigen (V-antigen, LcrV) of Yersinia pestis, the causative agent of bubonic plague, is an established protective antigen known to regulate, target, and mediate type III translocation of cytotoxic yersiniae outer proteins termed Yops; LcrV also prompts TLR2-dependent upregulation of anti-inflammatory IL-10. In this study, we determined the parameters of specific interaction of LcrV with TLR2 expressed on human transfected HEK293 cells (TLR2+/CD14-), VTEC2.HS cells (TLR2+/CD14-), primary monocytes (TLR2+/CD14+), and THP-1 cells (TLR2+/CD14+). The IRRL314-317 motif of the extracellular domain of human and mouse TLR2 accounted for high-affinity binding of LcrV. The CD14 co-receptor did not influence this interaction. LcrV did not bind to human U937 (TLR2-/CD14-) and alveolar macrophages (TLR2-/CD14+) in the absence of receptor-bound human IFN-gamma or a synthetic C-terminal fragment (hIFN-gamma132-143). The latter, but not mouse IFN-gamma (or synthetic control peptides), shared a GRRA138-141 site necessary for high-affinity specific binding. LcrV of Y. pestis shares the N-terminal LEEL32-35 binding site of Yersinia enterocolitica and also has an exposed internal DEEI203-206 binding site. Comparison of binding constants and consideration of steric restrictions indicate that binding is not cooperative and only the internal site binds LcrV to target cells. Both the LEEL32-35 and DEEI203-206 binding sites are removed by five amino acids from DKN residues associated with biological activity of bound LcrV. LcrV of Y. pestis promoted both TLR2/CD14-dependent and TLR2/CD14-independent amplification of IL-10 and concomitant downregulation of TNF-alpha in human target cells. The ability of LcrV to utilize human IFN-gamma (a major inflammatory effector of innate immunity) to minimize inflammation is insidious and may account in part for the severe symptoms of plague in man.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17441749     DOI: 10.1021/pr070036r

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  14 in total

1.  Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.

Authors:  Christine G Branger; Wei Sun; Ascención Torres-Escobar; Robert Perry; Kenneth L Roland; Jacqueline Fetherston; Roy Curtiss
Journal:  Vaccine       Date:  2010-10-24       Impact factor: 3.641

2.  Outsmarting the host: bacteria modulating the immune response.

Authors:  Matthew D Woolard; Jeffrey A Frelinger
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Amino acid and structural variability of Yersinia pestis LcrV protein.

Authors:  Andrey P Anisimov; Svetlana V Dentovskaya; Evgeniy A Panfertsev; Tat'yana E Svetoch; Pavel Kh Kopylov; Brent W Segelke; Adam Zemla; Maxim V Telepnev; Vladimir L Motin
Journal:  Infect Genet Evol       Date:  2009-10-14       Impact factor: 3.342

4.  Probiotic Properties of Lactobacillus crispatus 2,029: Homeostatic Interaction with Cervicovaginal Epithelial Cells and Antagonistic Activity to Genitourinary Pathogens.

Authors:  Vyacheslav Abramov; Valentin Khlebnikov; Igor Kosarev; Guldana Bairamova; Raisa Vasilenko; Natalia Suzina; Andrey Machulin; Vadim Sakulin; Natalia Kulikova; Nadezhda Vasilenko; Andrey Karlyshev; Vladimir Uversky; Michael L Chikindas; Vyacheslav Melnikov
Journal:  Probiotics Antimicrob Proteins       Date:  2014-12       Impact factor: 4.609

5.  Interleukin-10 induction is an important virulence function of the Yersinia pseudotuberculosis type III effector YopM.

Authors:  Joseph B McPhee; Patricio Mena; Yue Zhang; James B Bliska
Journal:  Infect Immun       Date:  2012-04-30       Impact factor: 3.441

6.  Yersinia pestis targets neutrophils via complement receptor 3.

Authors:  Peter M Merritt; Thomas Nero; Lesley Bohman; Suleyman Felek; Eric S Krukonis; Melanie M Marketon
Journal:  Cell Microbiol       Date:  2014-11-25       Impact factor: 3.715

7.  Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice.

Authors:  Ascención Torres-Escobar; María Dolores Juárez-Rodríguez; Bronwyn M Gunn; Christine G Branger; Steven A Tinge; Roy Curtiss
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

8.  Identification of a unique TLR2-interacting peptide motif in a microbial leucine-rich repeat protein.

Authors:  Srinivas R Myneni; Rajendra P Settem; Hakimuddin T Sojar; James P Malone; Vuokko Loimaranta; Takuma Nakajima; Ashu Sharma
Journal:  Biochem Biophys Res Commun       Date:  2012-06-10       Impact factor: 3.575

9.  Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.

Authors:  Wei Sun; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-07-24       Impact factor: 3.738

10.  Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.

Authors:  Christina L Airhart; Harold N Rohde; Carolyn J Hovde; Gregory A Bohach; Claudia F Deobald; Stephen S Lee; Scott A Minnich
Journal:  Vaccine       Date:  2008-08-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.